SereNeuro Therapeutics (CDL'25), a company developing non-opioid therapies for pain has close a pre-seed round. Its lead program SN101 is an off-the-shelf therapy made from purified human pain-sensing neurons derived from induced pluripotent stem cells.
prnewswire.com/news-releases/…
CDL's mission is to enhance the commercialization of science for the betterment of humankind #BuildSomethingMassive

